Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Clinical trial NCT04251182 · COMPLETED

Trial details

NCT number: NCT04251182
Sponsor: T3D Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alzheimer Disease

Start date: 2021-03-01
Primary completion: 2023-01-20
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.